Eventide Asset Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Eventide Asset Management’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-499,000	Closed	-$14M	–	142
2019 Q3	$14M	Hold	499,000	–	–	0.46%	68
2019 Q2	$18.9M	Hold	499,000	–	–	0.57%	65
2019 Q1	$19.5M	Buy	499,000 +224,000	+81%	+$6.42M	0.67%	57
2018 Q4	$5.86M	Hold	275,000	–	–	0.26%	84
2018 Q3	$10.9M	Hold	275,000	–	–	0.4%	74
2018 Q2	$10.5M	Buy	275,000 +5,000	+2%	+$185K	0.44%	69
2018 Q1	$8.11M	Buy	270,000 +45,000	+20%	+$1.52M	0.38%	70
2017 Q4	$7.03M	Hold	225,000	–	–	0.37%	72
2017 Q3	$6.3M	Hold	225,000	–	–	0.36%	72
2017 Q2	$4.3M	Hold	225,000	–	–	0.27%	75
2017 Q1	$3.83M	Hold	225,000	–	–	0.25%	80
2016 Q4	$4.11M	Hold	225,000	–	–	0.27%	75
2016 Q3	$4.01M	Buy	+225,000	New	+$3.41M	0.24%	74

Other funds holding BOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Eventide Asset Management's BOLD Position: Q4 2019 in Review

Eventide Asset Management sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 499,000 shares — an estimated $14M sold.

Eventide Asset Management first reported a position in BOLD in Q3 2016 and held it in 13 quarters. The position peaked at $19.5M in Q1 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

Eventide Asset Management reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
Eventide Asset Management sold 499,000 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $14M.
Eventide Asset Management first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 13 quarters.
Eventide Asset Management's Audentes Therapeutics, Inc position peaked at $19.5M in Q1 2019.
188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Eventide Asset Management's 13F filing for Q4 2019, filed 29 Jan 2020.